SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,643,680 | -64.8% | 1,284,000 | -49.3% | 0.40% | -58.8% |
| Q2 2023 | $52,957,923 | +46.5% | 2,530,240 | +47.8% | 0.96% | +35.2% |
| Q1 2023 | $36,150,576 | -29.2% | 1,711,675 | -14.7% | 0.71% | -27.3% |
| Q4 2022 | $51,065,425 | +5.9% | 2,006,500 | 0.0% | 0.98% | +9.2% |
| Q3 2022 | $48,216,000 | +7.9% | 2,006,500 | -13.6% | 0.90% | +10.5% |
| Q2 2022 | $44,700,000 | +19.2% | 2,323,300 | +7.6% | 0.81% | +33.2% |
| Q1 2022 | $37,511,000 | -13.5% | 2,158,300 | +8.9% | 0.61% | +9.0% |
| Q4 2021 | $43,371,000 | +1090.9% | 1,981,300 | +939.5% | 0.56% | +1295.0% |
| Q3 2021 | $3,642,000 | -86.0% | 190,600 | -83.7% | 0.04% | -82.5% |
| Q4 2020 | $26,041,000 | +61.3% | 1,170,900 | +7.0% | 0.23% | +12.3% |
| Q3 2020 | $16,149,000 | -0.4% | 1,094,100 | 0.0% | 0.20% | -11.0% |
| Q2 2020 | $16,215,000 | +409.7% | 1,094,100 | +277.3% | 0.23% | +330.2% |
| Q1 2020 | $3,181,000 | +70.9% | 290,000 | +36.8% | 0.05% | +96.3% |
| Q4 2019 | $1,861,000 | +17.5% | 212,000 | 0.0% | 0.03% | -10.0% |
| Q3 2019 | $1,584,000 | -19.8% | 212,000 | 0.0% | 0.03% | -3.2% |
| Q2 2019 | $1,974,000 | +77.4% | 212,000 | 0.0% | 0.03% | +82.4% |
| Q1 2019 | $1,113,000 | +18.0% | 212,000 | 0.0% | 0.02% | 0.0% |
| Q4 2018 | $943,000 | -73.3% | 212,000 | -51.5% | 0.02% | -60.5% |
| Q3 2018 | $3,531,000 | +15.1% | 437,000 | 0.0% | 0.04% | +16.2% |
| Q2 2018 | $3,068,000 | -50.7% | 437,000 | 0.0% | 0.04% | -51.9% |
| Q1 2018 | $6,219,000 | +62.5% | 437,000 | 0.0% | 0.08% | +60.4% |
| Q4 2017 | $3,828,000 | -25.1% | 437,000 | 0.0% | 0.05% | -2.0% |
| Q3 2017 | $5,113,000 | -16.2% | 437,000 | 0.0% | 0.05% | -23.4% |
| Q2 2017 | $6,105,000 | -8.2% | 437,000 | -9.9% | 0.06% | -14.7% |
| Q1 2017 | $6,651,000 | +22.5% | 484,800 | -36.0% | 0.08% | +8.7% |
| Q4 2016 | $5,430,000 | -52.7% | 757,365 | 0.0% | 0.07% | -47.3% |
| Q3 2016 | $11,482,000 | +53.9% | 757,365 | 0.0% | 0.13% | +67.9% |
| Q2 2016 | $7,460,000 | -26.1% | 757,365 | 0.0% | 0.08% | -26.4% |
| Q1 2016 | $10,088,000 | – | 757,365 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |